SCHEMBL25253389

SCHEMBL25253389

O=C(O)N1CC(c2ccc(F)nc2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
GLA P06280 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HIF1A Q16665 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SPR P35270 2/20 0.42
KDM1A O60341 2/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
SCD5 Q86SK9 4/20 0.38
SCD O00767 3/20 0.38
CHRNB2 P17787 1/20 0.35
CHRNA4 P43681 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
ATM Q13315 1/20 0.35
GRIN1 Q05586 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25261953 0.81 HTT (0.43) KDM4EGLAHTTKMT2ASMN1; SMN2
SCHEMBL162009 0.81 NAPRT (0.43) KDM4EGLAHTTKMT2ASMN1; SMN2
SCHEMBL159379 0.81 GABRP (0.43) KDM4EGLAHTTKMT2ASMN1; SMN2
SCHEMBL30395072 0.79 DDB1 (0.46) KDM4ESPR
SCHEMBL20757383 0.79 DDB1 (0.46) KDM4ESPR
SCHEMBL20743069 0.78 KDM1A (0.40) KMT2AKDM1AMAOAMAOB
SCHEMBL25257655 0.77 SMN1; SMN2 (0.40) KDM4EGLAHTTKMT2ASMN1; SMN2
SCHEMBL23211825 0.77 SLC6A2 (0.43) KDM4EGLAHTTKMT2ASMN1; SMN2
SCHEMBL25255898 0.76 SCD5 (0.38) KDM4EGLAHTTKMT2ASMN1; SMN2
SCHEMBL15513886 0.74 SLC18A3 (0.42) SMN1; SMN2SCD5SCDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11981661-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2024-05-14 US disclosed
EP-4208456-A1 HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2023-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11981661-B2 Heterocyclic compounds CBR3, BRIX1, CCNY KDM4E 1570/4885GLA 547/4885HTT 1702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.